Literatur
Ryckmanns F (1980) Hypertrichose durch Minoxidil. Hautarzt 31:205–206
De Groot A, Nater JP, Herxheimer A (1987) Minoxidil: Hope for the bald? Lancet 329:1019–1022
Olsen EA, DeLong ER, Weiner MS (1987) Long-term follow-up of men with male pattern baldness treated with topical minoxidil. J Am Acad Dermatol 16:688–695
Price VH, Menefee E, Strauss PC (1999) Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5 % and 2 % topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 41:717–721
Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, Trancik RJ (2002) A randomized clinical trial of 5 % topical minoxidil versus 2 % topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 47:377–385
Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, Savin RC, Tharp MD (2004) A randomized, placebo-controlled trial of 5 % and 2 % topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 50:541–553
Lachgar S, Charveron M, Gall Y, Bonafe JL (1998) Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 138:407–411
Messenger AG, Rundegren J (2004) Minoxidil: mechanisms of action on hair growth. Br J Dermatol 150:186–194
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
H. Wolff hat Vortrags- und Beraterhonorare der Minoxidil-Herstellerfirmen Pharmacia, Pfizer und Johnson & Johnson erhalten.
Rights and permissions
About this article
Cite this article
Wolff, H. Minoxidil. Hautarzt 67, 575–576 (2016). https://doi.org/10.1007/s00105-016-3822-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00105-016-3822-2